Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
Phase 3Completed 2 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Japanese Encephalitis
Conditions
Japanese Encephalitis, Measles, Mumps, Rubella
Trial Timeline
Aug 1, 2010 → Dec 1, 2012
NCT ID
NCT01188343About Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus
Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus + Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus is a phase 3 stage product being developed by Sanofi for Japanese Encephalitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01188343. Target conditions include Japanese Encephalitis, Measles, Mumps.
What happened to similar drugs?
3 of 20 similar drugs in Japanese Encephalitis were approved
Approved (3) Terminated (0) Active (17)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01188343 | Phase 3 | Completed |
Competing Products
20 competing products in Japanese Encephalitis